Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SPECTAZOLE is a topical cream small-molecule antifungal agent approved in 1982 for dermatological fungal infections. The product is currently owned by Alvogen and is approaching loss of exclusivity. Mechanism of action and specific indications are not disclosed in available data.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); expect consolidating commercial teams focused on maintaining market share rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SPECTAZOLE offers minimal career growth opportunity given its LOE-approaching status and zero linked job postings. Career development at this company/product is best suited for professionals seeking stable, maintenance-focused roles in commercial or regulatory functions rather than innovation or launch experience.
Worked on SPECTAZOLE at Alvogen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.